Jasper announces Health Canada clearance of trial application of briquilimab

Jasper Therapeutics announced that Health Canada has cleared the Company’s Clinical Trial Application, CTA, for a Phase 1b/2a asthma challenge study evaluating briquilimab in asthma. “We are excited to announce that Health Canada has issued a no objection letter allowing us to move forward with our first clinical trial evaluating briquilimab in asthma, and we look forward to commencing patient enrollment shortly,” said Edwin Tucker, M.D., Chief Medical Officer. “Our clinical development plan follows an established and efficient pathway beginning with a challenge study in patients with allergic asthma to enable rapid advancement of the program. We aim to demonstrate proof of concept for the depletion of mast cells with briquilimab as an effective mechanism of action in asthma and to inform potential future studies in the broader asthma population.”